NOIDA, India, Jan. 21 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in Noida near New Delhi, announced today that its subsidiary Jubilant Biosys Ltd., based in Bangalore, has developed a next generation screening solution, Legend NGSS(TM), that will further enable the process of high throughput screening, accelerating global drug discovery. The software to be launched in the US and Europe initially, allows scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed.
Legend NGSS(TM) allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.
“This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research,” said Christoph Pittius, PhD, Vice President, Global Business Development, Jubilant Biosys.
“This innovative product demonstrates Jubilant’s strategy to develop and provide enabling technologies to accelerate the process of Drug Discovery and Development,” he added further.
Legend NGSS(TM) has been developed in collaboration with a leading global pharmaceutical company. It is available worldwide on a subscription basis, which includes comprehensive software support and training. The product has generated substantial interest and response during prelaunch activities from global pharmaceutical companies involved in drug discovery.
About Jubilant Biosys
Jubilant Biosys Ltd. headquartered in Bangalore (http://www.jubilantbiosys.com), is a subsidiary of India-based Jubilant Organosys Ltd. It provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has 125,000 sq. ft. state-of-the-art facility in Bangalore, India. The center houses more than 500 scientists specializing in Bioinformatics, in vitro, in vivo biology, HTS, medicinal chemistry, structural biology, pharmacology, molecular modeling, information technology, and other scientific disciplines. The company has expanded relationships with the global pharmaceutical industry across the drug discovery and development value chain.
Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services company out of India. The Company’s consolidated sales in FY ’07-08 stood at over US$ 600 million.
CONTACT: Corey Jacklin, Director Business Development of Jubilant Biosys,
+1-215-369-0965, corey_jacklin@jubilantbiosys.com; or India, Media, Seema
Ahuja, VP - Corporate Marketing & Communications, +91-120-4361062, cell,
+91-9810631779, seema_ahuja@jubl.com, or Investors, Deepak Malik, Manager -
Investor Relations, +91-120 4361114, fax, +91-120-2516629,
deepak_malik@jubl.com, both of Jubilant Organosys Limited1-A, Sector 16-A,
Institutional Area, Noida - 201301 (UP)
Web site: http://www.jubilantbiosys.com/
